Company Status Ampio Pharmaceuticals is a development stage biopharma that closed its doors on August 16, 2024, indicating an opportunity to identify potential buyers, IP acquisition targets, or licensing partners for its assets, pipelines, or remaining research data.

Incurred Litigation Past class action litigation and advisory challenges suggest a need for risk management, potential reputational due diligence for acquirers, and opportunities to offer regulatory, compliance, or governance consulting services to successor entities or investors.

Board and Leadership A history of frequent leadership and board appointments indicates potential for legacy relationships with investors and advisers; sales outreach could target firms that historically engaged Ampio for strategic collaborations, licensing, or transition services.

Financial Position Revenue is minimal to none, signaling an opportunity for asset monetization, licensing deals, or collaboration arrangements to maximize value from any existing programs or IP assets for interested buyers in the inflammatory disease space.

Market Fit Focus on immunomodulatory therapies for inflammatory conditions aligns with larger market demand; identify potential buyers or partners with complementary platforms (biologics, small molecules, or device-enabled delivery) to accelerate development or commercialization of Ampio’s assets.